MedWatch

Veloxis parts ways with CEO

William J. Polvino is stepping down from his role as CEO of biotech company Veloxis just one week after its main asset, Envarsus, was launched in the US. He will be replaced by an experienced American.

William J. Polvino is leaving Veloxis after more than six years in charge of the biotech company as its Chief Executive Officer. He will be replaced at the helm by Craig A. Collard, who joins from a CEO position at BioMarck Pharmaceuticals, with immediate effect, the company says in a stock market release.

In his time in charge of the Danish company, William Polvino has helped develop and win approval for Envarsus, a drug used to prevent organ rejection in patients who undergo kidney transplants. His departure is announced on the same week when the drug was launched on the US market.

Allerede abonnent? Log ind.

Læs hele artiklen

Få adgang i 14 dage for 0 kr.
Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Relaterede

Seneste nyt

MedWatch job

Se flere jobs

Se flere jobs

Watch job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier